, ICD 10: I21 Arrhythmia First incident or fatal arrhythmia 14AN.00, vol.3272, p.3273

J. Ferlay, E. Steliarova-foucher, and J. Lortet-tieulent, Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012, Eur. J. Cancer, pp.49-1374, 2013.

R. Kockelbergh, L. Hounsome, and E. Mayer, The epidemiology of urological cancer 2001-2013, J. Clin. Urol, issue.1S, pp.3-8, 2017.

M. A. Perlmutter and H. Lepor, Androgen deprivation therapy in the treatment of advanced prostate cancer, Rev. Urol, issue.1, pp.3-8, 2007.

M. A. Khan and A. Partin, Management of high-risk populations with locally advanced prostate cancer, Oncologist, vol.8, pp.259-269, 2003.

M. Braga-basaria, A. S. Dobs, and D. C. Muller, Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy, J. Clin. Oncol, vol.24, pp.3979-3983, 2006.

N. L. Keating, A. J. O'malley, and M. R. Smith, Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer, J. Clin. Oncol, vol.24, pp.4448-4456, 2006.

D. G. Mcleod, P. Iversen, and W. A. See, Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer, BJU Int, pp.247-254, 2006.

P. J. Petrylak and J. W. Moul, Androgen Ablation for Prostate Cancer: Mechanisms and Modalities, pp.518-523, 2002.

C. S. Saigal, J. L. Gore, and T. L. Krupski, Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer, Cancer, pp.110-1493, 2007.

R. D. Jones, J. E. Nettleship, and D. Kapoor, Testosterone and atherosclerosis in aging men: purported association and clinical implications, Am. J. Cardiovasc. Drugs, vol.5, pp.141-154, 2005.

A. V. D'amico, J. W. Denham, and J. Crook, Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions, J. Clin. Oncol, vol.25, pp.2420-2425, 2007.

H. K. Tsai, A. V. D'amico, and N. Sadetsky, Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality, J. Natl Cancer Inst, pp.99-1516, 2007.

S. O'farrell, H. Garmo, and L. Holmberg, Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer, J. Clin. Oncol, pp.33-1243, 2015.

M. Van-hemelrijck, H. Garmo, and L. Holmberg, Absolute and relative risk of cardiovascular disease in men with prostate cancer: results from the Population-Based PCBaSe Sweden, J. Clin. Oncol, pp.28-3448, 2010.

J. Barkin, Risks, benefits, and approaches to hormonal blockade in prostate cancer, Highlights from the European Association of Urology Meeting, pp.22-7847, 2015.

P. C. Albertsen, L. Klotz, and B. Tombal, Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist, Eur. Urol, pp.65-565, 2014.

S. N. Hopmans, W. C. Duivenvoorden, and G. H. Werstuck, GnRH antagonist associates with less adiposity and reduced characteristics of metabolic syndrome and atherosclerosis compared with orchiectomy and GnRH agonist in a preclinical mouse model, Urol. Oncol, pp.32-1126, 2014.

D. J. Rosario, P. Davey, and J. Green, The role of gonadotrophin-releasing hormone antagonists in the treatment of patients with advanced hormone-dependent prostate cancer in the UK, World J. Urol, vol.34, pp.1601-1609, 2016.

. Clinicaltrials and . Gov, A trial comparing cardiovascular safety of degarelix versus leuprolide in patients with advanced prostate cancer and cardiovascular disease (PRONOUNCE), 2018.

L. M. Scailteux, S. Vincendeau, and F. Balusson, Androgen deprivation therapy and cardiovascular risk: no meaningful difference between GnRH antagonist and agonists -a nationwide population-based cohort study based on 2010-2013 French Health Insurance data, Eur. J. Cancer, vol.77, pp.99-108, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01519865

O. S. Miettinen, The need for randomization in the study of intended effects, Stat. Med, vol.2, pp.267-271, 1983.

K. Benson and A. J. Hartz, A comparison of observational studies and randomized, controlled trials, N. Engl. J. Med, vol.342, pp.1878-1886, 2000.

G. George, L. M. Scailteux, and H. Garmo, The risk of cardiovascular disease following GnRH agonists versus antagonists: real-world evidence from four European countries, pp.16-20, 2018.

G. George, L. M. Scailteux, and H. Garmo, Real-world insights into risk of cardiovascular disease following GnRH agonists and antagonists in men with prostate cancer, pp.27-28, 2018.

J. A. Sterne, M. A. Hern-an, and B. C. Reeves, ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions, Br. Med. J, vol.355, p.4919, 2016.

, The Authors. Fundamental & Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of Soci et e Franc ßaisede Pharmacologie et de Thé rapeutique Fundamental & Clinical Pharmacology, 2019.

R. K. Lodwick and . Thin, , 2015.

, IMS Health Incorporated. Data content, 2015.

N. Booth, What are the read codes?, Health Lib. Rev, pp.11-177, 1994.

S. Alvarez-madrazo, S. Mctaggart, and C. Nangle, Data resource profile: the Scottish national prescribing information system (PIS), Int. J. Epidemiol, pp.45-714, 2016.

, Belgian Cancer Registry. Belgian Cancer Registry, 2017.

B. Law, relating to the communication of personal data by insurers to the Cancer Registry Foundation under Article 45 quinquies of the Royal Decree number 78 of 10, 1967.

B. Law, Deliberation No. 16/021 of 15 March 2016 on the communication of coded personal health data by the technical unit to the Cancer Registry Foundation for the assessment of comorbidity in cancer patients in the context of scientific research projects

M. P. Van-herk-sukel, L. V. Van-de-poll-franse, and V. E. Lemmens, New opportunities for drug outcomes research in cancer patients: the linkage of the Eindhoven Cancer Registry and the PHARMO Record Linkage System, Eur. J. Cancer, vol.46, pp.395-404, 2010.

. Pharmo-institute, . Pharmo-database, and . Network, , 2017.

A. S. , , 2016.

J. Bezin, M. Duong, and R. Lassalle, The national healthcare system claims databases in France, SNIIRAM and EGB: Powerful tools for pharmacoepidemiology, Pharmacoepidemiol. Drug Saf, vol.26, pp.954-962, 2017.

J. P. Mackenbach, Inequality and the North, Health Policy, vol.10, issue.2, p.207, 1987.

C. M. Booth and I. F. Tannock, Randomised controlled trials and population-based observational research: partners in the evolution of medical evidence, Br. J. Cancer, vol.110, pp.551-555, 2014.

T. J. Vanderweele and P. Ding, Sensitivity analysis in observational research: introducing the E-value, Ann. Intern. Med, pp.167-268, 2017.

Q. Said, Understanding pharmacoepidemiology. The McGrawHill Companies, Other methodological issues, pp.105-120, 2010.

M. Clyne, Prostate cancer: tipping the balance in favour of degarelix for ADT, Nat. Rev. Urol, vol.11, p.67, 2014.

, Degarelix for treating advanced hormone-dependent prostate cancer. Final Scope, 2013.

, Prostate Cancer: diagnosis and treatment, 2014.

, Final Appraisal Determination: Degarelix for treating advanced hormonedependent prostate cancer, 2014.

, Royal Decree of 31/12/2001 -IV -2360000 -Law on various health provisions of, 2006.

, Transparency committee opinion Firmagon, 2009.

D. Boer and J. E. , CFH-rapport 09/19: degarelix (Firmagon â ), Degarelix+(Firmagon) + bij+ hormoonafhankelijke+prostaatkanker+in+een+ vergevorderd+stadium.pdf, 2009.

S. Suissa, Immeasurable time bias in observational studies of drug effects on mortality, Am. J. Epidemiol, pp.168-329, 2008.

. Inami-riziv, Nomenclature: research criteria, 2018.

, The Authors. Fundamental & Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of Soci et e Franc ßaisede Pharmacologie et de Thé rapeutique Fundamental & Clinical Pharmacology, 2019.